# OnCo record hussein-tawbi (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/hussein-tawbi/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "hussein-tawbi" ;
  schema:name "Hussein A. Tawbi"@en ;
  schema:description "Led RELATIVITY-047, which made relatlimab the first approved LAG-3 inhibitor, and the trial that showed immunotherapy works in melanoma brain metastases."@en ;
  schema:url <https://onco.cc/people/hussein-tawbi/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Tawbi%20HA%5BAuthor%5D%20melanoma%20relatlimab%20OR%20brain> ;
  onco:tag "melanoma", "lag3", "brain-metastases" ;
  schema:jobTitle "Professor and Deputy Chair, Department of Melanoma Medical Oncology, MD Anderson Cancer Center" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/lag3/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/relatlimab-nivolumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:institutions <https://onco.cc/institutions/md-anderson/> ;
  onco:trials <https://onco.cc/trials/relativity-047/>, <https://onco.cc/trials/relativity-098/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-relativity-047-nejm-2022/> ;
  schema:affiliation <https://onco.cc/institutions/md-anderson/> .